BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ, Trebicka J, Thevenot T, Arroyo V. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69:1127-1138. [PMID: 32102926 DOI: 10.1136/gutjnl-2019-318843] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Casulleras M, Zhang IW, López-Vicario C, Clària J. Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells 2020;9:E2632. [PMID: 33302342 DOI: 10.3390/cells9122632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ata F, As AK, Engin M, Kat NK, Ata Y, Turk T. Can blood urea Nitrogen-to-Albumin ratio predict mortality in patients with moderate-to-severe COVID-19 pneumonia hospitalized in the intensive care unit? Rev Assoc Med Bras (1992) 2021;67:1421-6. [PMID: 35018969 DOI: 10.1590/1806-9282.20210610] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Baldassarre M, Naldi M, Zaccherini G, Bartoletti M, Antognoli A, Laggetta M, Gagliardi M, Tufoni M, Domenicali M, Waterstradt K, Paterini P, Baldan A, Leoni S, Bartolini M, Viale P, Trevisani F, Bernardi M, Caraceni P. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology 2021. [PMID: 33710623 DOI: 10.1002/hep.31798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Jeng LB, Li TC, Hsu SC, Chan WL, Teng CF. Association of Low Serum Albumin Level with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection. J Clin Med 2021;10:4187. [PMID: 34575311 DOI: 10.3390/jcm10184187] [Reference Citation Analysis]
5 Casulleras M, Flores-Costa R, Duran-Güell M, Zhang IW, López-Vicario C, Curto A, Fernández J, Arroyo V, Clària J. Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. Hepatol Commun 2022. [PMID: 35178899 DOI: 10.1002/hep4.1893] [Reference Citation Analysis]
6 Cao J, Qiu W, Yu Y, Li N, Wu H, Chen Z. The association between serum albumin and depression in chronic liver disease may differ by liver histology. BMC Psychiatry 2022;22:5. [PMID: 34983435 DOI: 10.1186/s12888-021-03647-8] [Reference Citation Analysis]
7 Ripoll C, Zipprich A. Open or closed window: That is the question. J Hepatol 2021;74:485-6. [PMID: 33308874 DOI: 10.1016/j.jhep.2020.09.017] [Reference Citation Analysis]
8 Zhou J, Chen S, Zhang L, Zhai Y. Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report. Daru 2021. [PMID: 34817844 DOI: 10.1007/s40199-021-00420-w] [Reference Citation Analysis]
9 Grewal T, Buechler C. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. IJMS 2022;23:1070. [DOI: 10.3390/ijms23031070] [Reference Citation Analysis]
10 Schulz M, Trebicka J. Acute-on-chronic liver failure: a global disease. Gut 2021:gutjnl-2020-323973. [PMID: 33632711 DOI: 10.1136/gutjnl-2020-323973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Rajpurohit S, Musunuri B, Shailesh, Mohan PB, Shetty S. Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.01.012] [Reference Citation Analysis]
12 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
13 Li J, Li M, Zheng S, Li M, Zhang M, Sun M, Li X, Deng A, Cai Y, Zhang H. Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19. Biomark Med 2020;14:827-37. [PMID: 32490680 DOI: 10.2217/bmm-2020-0254] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
14 Nielsen MC, Hvidbjerg Gantzel R, Clària J, Trebicka J, Møller HJ, Grønbæk H. Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. Cells 2020;9:E1175. [PMID: 32397365 DOI: 10.3390/cells9051175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
15 Li Y, Li H, Song C, Lu R, Zhao Y, Lin F, Han D, Chen L, Pan P, Dai M. Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio. Dis Markers 2021;2021:6304189. [PMID: 34900028 DOI: 10.1155/2021/6304189] [Reference Citation Analysis]
16 Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 2021;74:670-85. [PMID: 33301825 DOI: 10.1016/j.jhep.2020.11.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
17 García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2020;2:100122. [PMID: 32671331 DOI: 10.1016/j.jhepr.2020.100122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
18 Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature . World J Hepatol 2021; 13(4): 421-432 [PMID: 33959225 DOI: 10.4254/wjh.v13.i4.421] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zaccherini G, Tufoni M, Iannone G, Caraceni P. Management of Ascites in Patients with Cirrhosis: An Update. J Clin Med 2021;10:5226. [PMID: 34830508 DOI: 10.3390/jcm10225226] [Reference Citation Analysis]
20 Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep 2021;3:100176. [PMID: 33205036 DOI: 10.1016/j.jhepr.2020.100176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Kakihara A, Maenohara S, Tokushige K, Ido A. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatol Res 2021;51:445-60. [PMID: 33533150 DOI: 10.1111/hepr.13622] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sharma P, Moore K, Ganger D, Grewal P, Brown RS. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. Liver Transpl 2020;26:1328-36. [DOI: 10.1002/lt.25834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 Fujiyama S, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study. BMC Gastroenterol 2021;21:189. [PMID: 33892649 DOI: 10.1186/s12876-021-01770-0] [Reference Citation Analysis]
24 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Qu F, Li Z, Lai S, Zhong X, Fu X, Huang X, Li Q, Liu S, Li H. Construction and Validation of a Serum Albumin-to-Alkaline Phosphatase Ratio-Based Nomogram for Predicting Pathological Complete Response in Breast Cancer. Front Oncol 2021;11:681905. [PMID: 34692474 DOI: 10.3389/fonc.2021.681905] [Reference Citation Analysis]
26 Otal Y, Avcıoglu G, Haydar FG. A new biomarker in severe pneumonia associated with coronavirus disease 2019: hypoalbuminemia. A prospective study. Sao Paulo Med J 2022:S1516-31802022005009201. [PMID: 35507997 DOI: 10.1590/1516-3180.2021.0066.R2.16082021] [Reference Citation Analysis]
27 Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol 2021;12:718783. [PMID: 34393832 DOI: 10.3389/fphys.2021.718783] [Reference Citation Analysis]
28 Kronborg TM, Ytting H, Hobolth L, Møller S, Kimer N. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study. Front Med (Lausanne) 2021;8:718896. [PMID: 34631742 DOI: 10.3389/fmed.2021.718896] [Reference Citation Analysis]
29 Yu H, Ren Y, Wei H, Xing W, Xu G, Li T, Xue M, Luo L. Dietary oxidized fish oil negatively affected the feed utilization, health status and fillet quality of juvenile Amur sturgeon, A. schrenckii. Aquaculture 2022;546:737290. [DOI: 10.1016/j.aquaculture.2021.737290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.J Hepatol. 2021;74:819-828. [PMID: 33075344 DOI: 10.1016/j.jhep.2020.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
31 Lin H, Fan Y, Wieser A, Zhang J, Regel I, Nieß H, Mayerle J, Gerbes AL, Steib CJ. Albumin Might Attenuate Bacteria-Induced Damage on Kupffer Cells for Patients with Chronic Liver Disease. Cells 2021;10:2298. [PMID: 34571946 DOI: 10.3390/cells10092298] [Reference Citation Analysis]
32 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Rao B H, Nair P, Koshy AK, Krishnapriya S, Greeshma CR, Venu RP. Role of High-Density Lipoprotein Cholesterol (HDL-C) as a Clinical Predictor of Decompensation in Patients with Chronic Liver Disease (CLD). Int J Hepatol 2021;2021:1795851. [PMID: 34976412 DOI: 10.1155/2021/1795851] [Reference Citation Analysis]
34 Bastati N, Beer L, Ba-Ssalamah A, Poetter-Lang S, Ambros R, Kristic A, Lauber D, Pomej K, Binter T, Simbrunner B, Semmler G, Balcar L, Bican Y, Hodge JC, Wrba T, Trauner M, Reiberger T, Mandorfer M. Gadoxetic Acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and Spleen Diameter Predict Outcomes in ACLD. J Hepatol 2022:S0168-8278(22)00268-9. [PMID: 35525337 DOI: 10.1016/j.jhep.2022.04.032] [Reference Citation Analysis]
35 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Rodina AS, Shubina ME, Kurbatova IV, Topchieva LV, Dudanova OP. Hepatocytic Apoptosis and Immune Dysfunction in Decompensation of Alcoholic Liver Cirrhosis with Different Grades of Acute-on-Chronic Liver Failure. Bull Exp Biol Med 2022. [PMID: 35175469 DOI: 10.1007/s10517-022-05404-7] [Reference Citation Analysis]
37 Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 2021;75 Suppl 1:S49-66. [PMID: 34039492 DOI: 10.1016/j.jhep.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Wang N, Yao W, Ma R, Ren F. The efficacy of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25535. [PMID: 33879696 DOI: 10.1097/MD.0000000000025535] [Reference Citation Analysis]
39 Uyar E, Merdin A, Yamanyar S, Ezgü MC, Artuk C, Taşkın G, Arslan Y, Ceritli S. Could serum albumin value and thrombocyte/lymphocyte ratio be an important prognostic factor in determining the severity of COVID 19? Turk J Med Sci 2021;51:939-46. [PMID: 33350294 DOI: 10.3906/sag-2008-285] [Reference Citation Analysis]
40 Mehta G, Jalan R. The "Alter Ego" of Albumin in Cirrhosis. Hepatology 2021. [PMID: 34009686 DOI: 10.1002/hep.31908] [Reference Citation Analysis]
41 Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol 2021;27:437-45. [PMID: 33504138 DOI: 10.3350/cmh.2020.0329] [Reference Citation Analysis]
42 Castro-Narro G, Moctezuma-Velázquez C, Male-Velázquez R, Trejo-Estrada R, Bosques FJ, Moreno-Alcántar R, Rodríguez-Hernández H, Bautista-Santos A, Córtez-Hernández C, Cerda-Reyes E, Pérez-Escobar J, Aldana-Ledesma JM, Aguirre-Valadez J, Ruiz-Velasco JAV, Contreras-Omaña R, Miranda-Zazueta G, Reyes-Bastidas MDR, Meza-Cardona JM, Chávez-Tapia N, Fernández-Pérez NJ, García-Jiménez ES, Torre A. POSITION STATEMENT ON THE USE OF ALBUMIN IN LIVER CIRRHOSIS. Ann Hepatol 2022;:100708. [PMID: 35550187 DOI: 10.1016/j.aohep.2022.100708] [Reference Citation Analysis]
43 Michel M, Hess C, Kaps L, Kremer WM, Hilscher M, Galle PR, Moehler M, Schattenberg JM, Wörns MA, Labenz C, Nagel M. Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. Sci Rep 2021;11:20506. [PMID: 34654829 DOI: 10.1038/s41598-021-00119-7] [Reference Citation Analysis]
44 Farrugia A. The interphase between immunoglobulin, the plasma industry and the public health, managing a finite resource. Transfus Clin Biol 2021;28:86-8. [PMID: 33358661 DOI: 10.1016/j.tracli.2020.12.004] [Reference Citation Analysis]
45 Grüngreiff K, Gottstein T, Reinhold D, Blindauer CA. Albumin Substitution in Decompensated Liver Cirrhosis: Don't Forget Zinc. Nutrients 2021;13:4011. [PMID: 34836265 DOI: 10.3390/nu13114011] [Reference Citation Analysis]
46 Bernal W, Karvellas C, Saliba F, Saner FH, Meersseman P. Intensive care management of acute-on-chronic liver failure. J Hepatol 2021;75 Suppl 1:S163-77. [PMID: 34039487 DOI: 10.1016/j.jhep.2020.10.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Casulleras M, Flores-costa R, Duran-güell M, Alcaraz-quiles J, Sanz S, Titos E, López-vicario C, Fernández J, Horrillo R, Costa M, de la Grange P, Moreau R, Arroyo V, Clària J. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. Sci Transl Med 2020;12. [DOI: 10.1126/scitranslmed.aax5135] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
48 Liu W, Pu Y, Zhu C, Qin A. Establishment of a scoring model for early diagnosis of infection associated with liver failure. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100713] [Reference Citation Analysis]
49 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
50 Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, Torimura T. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol 2021;14:79. [PMID: 33758660 DOI: 10.3892/mco.2021.2241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
52 Clària J, Curto A, Moreau R, Colsch B, López-Vicario C, Lozano JJ, Aguilar F, Castelli FA, Fenaille F, Junot C, Zhang I, Vinaixa M, Yanes O, Caraceni P, Trebicka J, Fernández J, Angeli P, Jalan R, Arroyo V. Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. J Hepatol 2021:S0168-8278(21)01895-X. [PMID: 34245803 DOI: 10.1016/j.jhep.2021.06.043] [Reference Citation Analysis]
53 Jiang G, Du X, Zhu Y, Zhang M, Qin W, Xiong T, Ou Y, Vialle LR. Value of Postoperative Serum Albumin to Predict Postoperative Complication Severity in Spinal Tuberculosis. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/4946848] [Reference Citation Analysis]
54 Farrugia A, Mori F. Therapeutic solutions of human albumin - The possible effect of process-induced molecular alterations on clinical efficacy and safety. J Pharm Sci 2022:S0022-3549(22)00111-3. [PMID: 35276228 DOI: 10.1016/j.xphs.2022.03.005] [Reference Citation Analysis]
55 Wiedermann CJ. Phases of fluid management and the roles of human albumin solution in perioperative and critically ill patients. Curr Med Res Opin 2020;36:1961-73. [PMID: 33090028 DOI: 10.1080/03007995.2020.1840970] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
56 Wiedermann CJ. Hypoalbuminemia as Surrogate and Culprit of Infections. Int J Mol Sci 2021;22:4496. [PMID: 33925831 DOI: 10.3390/ijms22094496] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Guldiken N, Argemi J, Gurbuz B, Atkinson SR, Oliverius M, Fila P, Hamesch K, Bruns T, Cabezas J, Lozano JJ, Mann J, Cao S, Mathurin P, Shah VH, Trautwein C, Thursz MR, Bataller R, Strnad P. Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. BMC Med 2021;19:39. [PMID: 33593348 DOI: 10.1186/s12916-021-01917-6] [Reference Citation Analysis]
58 Caraceni P, O'Brien A, Gines P. Long-term albumin treatment in patients with cirrhosis and ascites. J Hepatol 2022;76:1306-17. [PMID: 35589252 DOI: 10.1016/j.jhep.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Sharma S, Agarwal S, Gopi S, Anand A, Mohta S, Gunjan D, Yadav R, Saraya A. Determinants of Outcomes in Autoimmune Hepatitis Presenting as Acute on Chronic Liver Failure Without Extrahepatic Organ Dysfunction upon Treatment With Steroids. J Clin Exp Hepatol 2021;11:171-80. [PMID: 33746441 DOI: 10.1016/j.jceh.2020.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]